Justin J. Ellis

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

Paolo Neviani, Jason G. Harb, Joshua J. Oaks et al. · Journal of Clinical Investigation · 2013 · 219 citations · Full text

Medicine, Oncology, Pharmacology +16

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

Christopher J. Walker, Joshua J. Oaks, Ramasamy Santhanam et al. · Blood · 2013 · 146 citations · Full text

Medicine, Oncology, Pharmacology +10

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions

Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci et al. · Blood Cancer Discovery · 2020 · 34 citations · Full text

Medicine, Cell Biology, Oncology +17

Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform

Ragu Kanagasabai, Lucas D. Serdar, Soumendrakrishna Karmahapatra et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 21 citations

Medicine, Molecular Biology, Oncology +15

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target

Jason G. Harb, Paolo Neviani, Brenda Chyla et al. · Leukemia · 2013 · 19 citations

Life Sciences, Cancer Biology, Oncology +9